Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;57(2):218-229.
doi: 10.3947/ic.2024.0127. Epub 2025 Apr 17.

Genotypic Distribution of Alpha-Like Proteins in Group B Streptococcus Strains Isolated in Korea: Implications for Vaccine Coverage

Affiliations

Genotypic Distribution of Alpha-Like Proteins in Group B Streptococcus Strains Isolated in Korea: Implications for Vaccine Coverage

Ji Hyen Lee et al. Infect Chemother. 2025 Jun.

Abstract

Background: Group B Streptococcus (GBS) is a major cause of invasive bacterial diseases, including sepsis, meningitis, and pneumonia, particularly in newborns and infants. Pregnant adults, those with pre-existing conditions, and older adults are particularly susceptible. Ongoing research is focused on developing various vaccines utilizing different antigens, including capsular polysaccharides and alpha-like proteins (Alps). Epidemiological data on these antigens in GBS is essential for predicting the effectiveness of these vaccines. However, no epidemiological studies on Alps genotype have been conducted in Korea. This study aimed to fill this gap by investigating the distribution and characteristics of the alp genotype in domestic clinical strains.

Materials and methods: We analyzed 386 GBS strains isolated from various clinical specimens between April 2000 and November 2018. The serotype of each strain was initially verified using a slide latex agglutination reaction, then confirmed by polymerase chain reaction to determine the presence of the genes bca, rib, alp1, alp2, alp3, and alp4 associated with Alps. Strains were then classified as invasive or non-invasive based on the type of clinical specimen. The distribution of serotypes and alp genotype was analyzed across these classifications.

Results: We analyzed 386 bacterial strains to assess their clinical characteristics, serotypes, and alp genotype distributions. Of these strains, 47.1% (182 strains) were invasive primarily isolated from blood samples (43.3%, 167 strains), whereas non-invasive strains were more frequently isolated from sites such as the vagina and urethra. Serotype III was the most prevalent across both invasive and non-invasive strains, comprising 28.2% (109 strains) of all isolates. Notably, 79.5% (307 strains) of all isolates were encompassed by the hexavalent vaccine (serotype Ia, Ib, II, III, and V) formulations. Furthermore, the rib genotype was the most common, detected in 39.4% (152 strains) of all isolates, with a higher prevalence in non-invasive samples (44.1%, 90 strains).

Conclusion: Although the distribution of alp genotypes differed between invasive and non-invasive strains, the proportion of bca and rib was substantial. Therefore, Alp protein vaccine containing Rib and Cα antigens is expected to provide protection against prevalent GBS strains in Korea. Additional epidemiological studies on GBS vaginal colonization in pregnant women and invasive neonatal strains are needed to support early neonatal sepsis prevention in these high-risk groups.

Keywords: Genotype; Infant; Serogroup; Streptococcus agalactiae; Vaccine.

PubMed Disclaimer

Conflict of interest statement

DSJ is an associated editor of Infect Chemother and HWK is a member of editorial board of Infect Chemother; however, they were not involved in the peer reviewer selection, evaluation, and decision process of this article. Otherwise, no potential conflicts of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. Serotypes distribution of group B Streptococcus isolated in invasive and non-invasive strains (A). Serotype coverage comparison of trivalent (blue dashed line) and hexavalent vaccines (red dashed line) (B).
Figure 2
Figure 2. alp genotype distribution of group B Streptococcus isolated in invasive and non-invasive strains (A). The bca and rib genotypes, which have been extensively studied in the context of vaccines and are clinically significant, appear to constitute 72.3% of the samples (red dashed line) (B).
Figure 3
Figure 3. Serotypes and alp genotypes distribution of group B Streptococcus isolated in invasive strains. The serotype coverage of the trivalent vaccine (solid blue line) is 64.8%, while the serotype coverage of the hexavalent vaccine (dashed red line) is 86.26%. The bca and rib genotypes were identified in 67.6% of invasive strains.

Similar articles

References

    1. Kobayashi M, Schrag SJ, Alderson MR, Madhi SA, Baker CJ, Sobanjo-Ter Meulen A, Kaslow DC, Smith PG, Moorthy VS, Vekemans J. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016. Vaccine. 2019;37:7307–7314. - PMC - PubMed
    1. Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis. 2001;33:556–561. - PubMed
    1. Le Doare K, Heath PT. An overview of global GBS epidemiology. Vaccine. 2013;31(Suppl 4):D7–12. - PubMed
    1. Sendi P, Johansson L, Norrby-Teglund A. Invasive group B Streptococcal disease in non-pregnant adults : a review with emphasis on skin and soft-tissue infections. Infection. 2008;36:100–111. - PubMed
    1. Nuccitelli A, Rinaudo CD, Maione D. Group B Streptococcus vaccine: state of the art. Ther Adv Vaccines. 2015;3:76–90. - PMC - PubMed